Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
AstraZeneca
Merck
Baxter
McKesson

Last Updated: May 27, 2022

Angiotensin ii acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for angiotensin ii acetate and what is the scope of patent protection?

Angiotensin ii acetate is the generic ingredient in one branded drug marketed by La Jolla Pharma and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Angiotensin ii acetate has thirty-seven patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for angiotensin ii acetate
Recent Clinical Trials for angiotensin ii acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
American Lung AssociationPhase 2
Johns Hopkins UniversityPhase 2
National Heart, Lung, and Blood Institute (NHLBI)Phase 2

See all angiotensin ii acetate clinical trials

Pharmacology for angiotensin ii acetate
Drug Class Vasoconstrictor
Physiological EffectVasoconstriction
Medical Subject Heading (MeSH) Categories for angiotensin ii acetate
Anatomical Therapeutic Chemical (ATC) Classes for angiotensin ii acetate
Paragraph IV (Patent) Challenges for ANGIOTENSIN II ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GIAPREZA Injection angiotensin ii acetate 2.5 mg/mL 209360 1 2021-12-21

US Patents and Regulatory Information for angiotensin ii acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-002 Dec 21, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for angiotensin ii acetate

Country Patent Number Title Estimated Expiration
Slovenia 2986308 See Plans and Pricing
Japan 2017501154 低血圧治療のための単独または併用使用されるアンギオテンシンII See Plans and Pricing
Poland 2986308 See Plans and Pricing
Croatia P20200009 See Plans and Pricing
Australia 2017205168 Methods for administering angiotensin II See Plans and Pricing
China 111920939 血管紧张素II单独或以组合方式用于治疗低血压 (Angiotensin ll alone or in combination for the treatment of hypotension) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Colorcon
Baxter
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.